Navigation Links
PharmAthene Reports Third Quarter 2013 Financial And Operational Results
Date:11/7/2013

, in May 2013, the Delaware Supreme Court issued its ruling on the appeal in our litigation with SIGA Technologies, affirming the Court of Chancery's finding that SIGA was liable for breach of contract, reversing its finding of promissory estoppel, and remanding the case back to the Court of Chancery to reconsider the appropriate remedy and award of attorney's fees and expert witness costs in light of the Supreme Court's opinion. For more information about PharmAthene, please visit www.PharmAthene.com.

About TheracloneTheraclone is a biopharmaceutical company focused on the discovery and development of novel, monoclonal antibody therapeutics for diseases that are devastating for patients and their families and which are a significant threat to human health. Theraclone leverages its proprietary antibody discovery technology, I-STAR™ (In-Situ Therapeutic Antibody Rescue), to identify rare human antibodies that may be developed into antibody product candidates that are potentially safer and more effective than current therapies. Theraclone has a portfolio of innovative antibodies in clinical and preclinical development targeting serious medical conditions with a significant unmet medical need and a primary focus on infectious disease and cancer, which include:

  • TCN-032 - a recombinant fully human monoclonal antibody for the treatment of patients hospitalized with serious influenza
  • TCN-202 - a recombinant fully human monoclonal antibody for the treatment and prevention of cytomegalovirus, or CMV infections
  • For more information about Theraclone, please visit www.theraclone-sciences.com. On August 1, 2013, Theraclone and PharmAthene (NYSE MKT: PIP) announced a definitive merger agreement.

    Important Additional Information about the Proposed MergerThis communication is being made in connection with the proposed merger involving PharmAthene
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. PharmAthene to Present at Rodman & Renshaw Annual Global Investment Conference
    2. PharmAthene and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets
    3. PharmAthene Reports First Quarter 2013 Financial And Operational Results
    4. New Data Show PharmAthenes Recombinant Bioscavenger Binds To A Broad Spectrum Of Chemical Nerve Agents
    5. SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
    6. Pharmacyclics Reports Third Quarter 2013 Results
    7. CareFusion Reports First Quarter Fiscal 2014 Results
    8. Sequenom, Inc. Reports Financial Results For The Third Quarter Of 2013
    9. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
    10. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
    11. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... Calif. , Sept. 17, 2014 /PRNewswire-iReach/ -- Gradian ... The Tech Awards 2014, one of 10 global innovators ... global change. The Tech Awards, a signature program of The ... selected Gradian as one of two laureates in the Nokia ... Gradian equips hospitals around the world to ...
    (Date:9/17/2014)... MUMBAI, India , September 17, 2014 ... TRPA1 antagonist, GRC 17536, has shown positive data in ... with painful diabetic neuropathy , ... Transient Receptor Potential Ankyrin 1 (TRPA1) antagonist, GRC 17536 ... blind, placebo controlled, multi-centre, proof of concept study conducted ...
    (Date:9/17/2014)... Sept. 17, 2014  Millions of people suffer from neck ... Recently the FDA approved the launch of ... innovative implant device developed by Spinal Kinetics, which may offer ... and or arm pain. Hospital for Special Surgery (HSS), the ... hospital in New York City and ...
    Breaking Medicine Technology:Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2
    ... SOUTH PLAINFIELD, N.J., March 30, 2011 PTC Therapeutics, ... Spiegel M.D., FACP as Chief Medical Officer.  Dr. Spiegel ... also announced today the promotion of Jay Barth, M.D. ... (Logo: https://photos.prnewswire.com/prnh/20010919/PTCLOGO) Dr. Spiegel will report to ...
    ... 2011 Cempra Pharmaceuticals Inc. today announced presentations at ... chief executive officer, will present at the Needham & ... April 6, at The New York Palace Hotel in ... Cempra, will also be in attendance.  Dr. Fernandes will ...
    Cached Medicine Technology:PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 2PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 3Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences 2
    (Date:9/17/2014)... (HealthDay News) -- Present-day Europeans are the descendants ... according to a new study. Previous ... and early European farmers. But, a new genetic ... also the descendants of Ancient North Eurasians. Nearly ... third ancestral group, researchers from Harvard Medical School ...
    (Date:9/17/2014)... 2014 (HealthDay News) -- Managing diabetes, quitting smoking, controlling ... can reduce the risk for dementia -- even late ... World Alzheimer Report 2014, commissioned by Alzheimer,s Disease International, ... by 50 percent. The study noted that obesity and ... as well as high blood pressure. The ...
    (Date:9/17/2014)... Thompson HealthDay Reporter ... dieters who turn to artificial sweeteners to soothe their ... a new Israeli study suggests. Artificial sweeteners can ... calories, researchers found in human and mouse studies. ... the bacteria residing in the intestines in ways that ...
    (Date:9/17/2014)... Mathematics might be able to reduce the need ... to the autoimmune disease lupus. , In a new ... the progression from nephritis kidney inflammation to ... cannot reverse. A kidney biopsy is the only existing ... and its extent. , The model could also be ...
    (Date:9/17/2014)... Research has shown that most 18-month-olds learn an ... however, little is known about how children process information ... preschool years. In a new study, a University of ... as they age, and a limit exists as to ... findings could help parents enhance their children,s vocabularies and ...
    Breaking Medicine News(10 mins):Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:Babies learn words differently as they age, researcher finds 2
    ... an effective vaccine against recurrent kidney cancers.// Kidney cancer ... causes about 12,000 deaths in the United States every ... 50s and 60s. Standard treatment involves removal of all ... however, kidney cancer does not respond well to subsequent ...
    ... shown that a chemotherapy regimen combining vinorelbine (Navelbine) and ... the treatment of hormone-refractory prostate cancer . Specialists say ... in their disease. , However researchers added ... regimen is planned. From a group of 66 patients ...
    ... Breast cancer survivors can now get up and ... // older women, reported higher body esteem and ... a new study. ,Researchers compared 40 ... sedentary women, all early-stage breast cancer survivors. Regular ...
    ... has shown that there may be a link of type ... blood has high amounts of iron.// ,In this ... with no history of diabetes, cardiovascular disease or cancer. 700 ... iron concentration of 109 nanograms/milliliter manifested with diabetes whereas ...
    ... placing a soft plastic tube or catheter into the ... Patients must undergo training for two weeks and ... from the comfort of their home. Hemodialysis patients can ... attached to a blood-cleaning machine at a dialysis center. ...
    ... replacement therapy among breast cancer survivors has been // stopped ... or new cancers. ,Swedish researchers embarked on the study ... therefore subject to the same menopausal symptoms as other women. ... five years. After the initial 345 women in the study ...
    Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
    ... is designed for the repair of abdominal ... that has two distinct sides. One ... a layer of sodium hyaluronate and carboxymethylcellulose ... This coated side is bioresorbable, providing a ...
    ... The Hernia Repair Company, we recognize that ... limited fibrous tissue in-growth between the prosthesis ... polypropylene mesh. Like all the products in ... produces a clinically proven, versatile repair.,The Reconix ...
    ... is the first hernia repair material ... operative contamination of the material. This ... preservative agents, silver carbonate and chlorhexidine ... colonization on the patch for up ...
    ... Since its introduction in 1958, Bard mesh ... other products are compared. Bard mesh was ... first developed the "tension-free" hernia repair many ... "a safe and ideal" substance for permanent ...
    Medicine Products: